移植用HLAタイピング市場：製品・サービス、技術、移植タイプ、用途、エンドユーザー別-2024-2030年世界予測

移植用HLAタイピング市場規模は、2023年に9億9,831万米ドルと推定され、2024年には10億8,639万米ドルに達し、CAGR 9.09%で2030年には18億3,658万米ドルに達すると予測されています。

ヒト白血球抗原（HLA）タイピングは、HLA抗原として知られる細胞表面の特定のタンパク質を特定する、移植医療に不可欠なプロセスです。移植のためのHLAタイピングは、臓器移植、組織移植、幹細胞移植のドナーとレシピエントの適合性を確認し、適合させ、監視するために使用されます。このプロセスは、移植片拒絶反応のリスクを減らし、患者の転帰全体を改善することによって、移植を成功させるために極めて重要です。さらに、臓器移植に対する需要の高まりは、腎不全、肝硬変、心不全、糖尿病、血液疾患などの慢性疾患の増加によるものです。精密医療の進歩は、ドナーとレシピエント間の適合性を向上させるために、個々の遺伝子構成に基づく個別化アプローチにつながります。しかし、このような検査を行うには、より多くの訓練を受けた専門家が必要であり、また、臓器移植の同意方針をめぐる倫理的な懸念があるため、ヒト白血球抗原（HLA）プロセスの成長が制限されています。さらに、次世代シークエンシング（NGS）、PCRベースの技術、サンガーシークエンシングなどのHLAタイピング法の技術的進歩は、精度の向上とドナーとレシピエントのマッチングプロセスの迅速化に寄与しています。臓器提供を推進する啓蒙キャンペーンやヘルスケア・インフラへの投資による政府の支援は、市場の拡大をさらに後押ししています。

技術高い特異性と再現性による分子アッセイ技術の採用

分子アッセイ技術は、その高い分離能、特異性、再現性により、採用が増加しています。配列に基づくタイピング（SBT）技術では、HLA遺伝子のエクソン領域の配列を決定し、ドナーまたは患者サンプルに存在する対立遺伝子を決定します。この方法は可能な限り高い解像度を提供し、ドナーとレシピエントの正確なマッチングを可能にします。さらに、ポリメラーゼ連鎖反応（PCR）法は、標的HLA遺伝子領域の増幅に続いて、プローブのハイブリダイゼーションまたは制限断片長多型（RFLP）分析を行い、特定の対立遺伝子を同定するものです。非分子アッセイ技術には、血清学的および細胞学的手法によるHLAタイピングが含まれます。これらは主に、低分解能のタイピングで十分な場合や、コストやリソースの制約により分子法が利用できない場合に使用されます。血清学的手法では、以前にタイピングされた個体から得られた抗血清を用いて、特定のHLA抗原の存在について血清サンプルを検査します。細胞アッセイ法では、ドナーとレシピエントの免疫細胞が互いに反応する能力をin-vitroで測定することにより、両者の適合性を評価します。

製品とサービス：データの解釈と検査室のワークフロー管理を容易にするソフトウェアとサービスの優先順位

HLAタイピングのプロセスでは、正確で効率的な移植適合性検査結果を提供する機器が重要な役割を果たします。これにはシーケンサー、PCRベースの機器、その他の検査機器が含まれます。試薬と消耗品は、検査結果の再現性、感度、特異性、信頼性を保証するため、HLAタイピングプロセスに不可欠な要素です。これは、DNA増幅試薬、DNA配列決定試薬（NGSベース）、プローブ・ハイブリダイゼーション・アッセイ用キット、マイクロアレイ／固相アッセイ、およびラボで使用される品質管理材料と標準物質で構成されています。ソフトウェアとサービスは、データの解釈、結果の報告、検査室のワークフロー管理を容易にするため、HLAタイピングプロセスに不可欠です。データ解析のためのソフトウェア、データベース管理システム、および技能試験のための品質保証プログラムが使用されます。

移植の種類：白血病、リンパ腫、骨髄腫、免疫系疾患に対する幹細胞移植療法の利用が増加しています。

臓器移植は、損傷した臓器や機能しない臓器を、ドナーからの健康な臓器と置き換えるものです。幹細胞移植は、白血病、リンパ腫、骨髄腫、免疫系疾患など、血液に関するさまざまな疾患の治療法です。これは、損傷したり機能不全に陥ったりした細胞と置き換えるために、健康な造血幹細胞を患者に移植することを含みます。幹細胞移植におけるHLAタイピングは、ドナーとレシピエントの細胞の適合性を確保し、移植片対宿主病（GVHD）のリスクを軽減するために不可欠です。組織移植では、角膜、骨髄、血管、皮膚などの健康なドナー組織をレシピエントに移植し、臓器の機能を回復させたり、患者の生活の質を向上させたりします。

応用臓器移植の診断用途におけるHLAタイピングの使用

HLAタイピングは、臓器移植、造血幹細胞移植、輸血医療において、ドナーとレシピエント間の適合性を確認するための診断用途に適しています。HLAタイピングは、移植片拒絶反応のリスクを低減し、患者の予後を改善するために、適合する臓器を特定するのに役立ちます。HLAタイピングは、集団遺伝学、疾患関連研究、ワクチン開発、薬理ゲノミクス研究、精密医療構想などの研究用途に広く使用されています。さらに、HLAタイピングは、医学の進歩を支える強固なデータを生成するための効率的なツールを提供します。

エンドユーザー：ハイスループット機能とスケーラビリティを求める独立したリファレンスラボでの高い普及率

病院と移植センターは、移植用HLAタイピングの目的のために中核的なエンドユーザー・セグメントを形成しています。これらの施設では、ドナーとレシピエント間の適合性を判定するために組織タイピングを行い、臓器移植や骨髄移植の成功を保証しています。HLAは、HLAタイピングサービスにおいて、迅速な納期、高い精度、費用対効果の高いソリューションを提供しています。独立した標準検査機関は、HLAタイピングのような専門的な診断検査サービスを病院や移植センターに商業的に提供しています。高スループット能力、拡張性、効率を高める技術的進歩により、これらの検査機関は好まれています。研究機関や学術機関は、次世代シーケンシング（NGS）、PCRベース法、HLAタイピングのためのサンガーシーケンシングなどの高度な技術を用いて、移植生物学に関する科学的研究を行っています。この分野では主に、革新的な技術、使いやすいプラットフォーム、新しい調査手法のシームレスな導入を促進する広範なサポートサービスを求めています。

地域別インサイト

移植用ヒト白血球抗原（HLA）タイピング市場は、技術の進歩と多数の臓器移植手技の利用可能性により、世界中で大きな成長を遂げています。米国とカナダでは、臓器移植のニーズの高まりにより、HLAタイピングの需要が増加しています。米国国立衛生研究所（NIH）は、HLAタイピング技術を向上させるために数多くの研究イニシアチブに資金を提供しています。さらに、南北アメリカのヒト白血球抗原（HLA）タイピング市場は、より正確なHLAタイピング結果につながる技術の進歩とともに、医師と患者の双方における臓器移植に対する意識の高まりにより、高い成長率が見込まれています。欧州では、臓器移植を必要とする慢性疾患の有病率を高める高齢化などの要因により、HLAタイピングサービスに対する需要が着実に増加しています。さらに、有利な償還政策が、欧州で移植手術を受ける患者を支援しています。サウジアラビア臓器移植学会（SSOT）のような組織は、湾岸協力会議（GCC）臓器移植プログラムのような国家間の意識向上と協力関係の強化に取り組んでいます。中国、日本、インドでは、遺伝性疾患の有病率が高く、臓器移植のニーズが高まっているため、HLAタイピングの需要が高まっています。中国の国家自然科学基金（National Natural Science Foundation）は、新しいHLAタイピング技術に関する研究に資金を提供しています。さらに日本の厚生労働省は、日本移植・細胞治療学会（JSTCT）などのプロジェクトを支援しています。インドでは、「全国臓器・組織移植機構（NOTTO）」などの政府の取り組みが、臓器提供に関する国民の意識を高めることで市場の成長に貢献しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは移植用HLAタイピング市場を評価する上で極めて重要です。事業戦略や製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、移植用HLAタイピング市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力について徹底的な評価を行います。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.移植用HLAタイピング市場の市場規模および予測は？

2.移植用HLAタイピング市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.移植用HLAタイピング市場の技術動向と規制枠組みは？

4.移植用HLAタイピング市場における主要ベンダーの市場シェアは？

5.移植用HLAタイピング市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 骨髄、臓器、血液移植手術の発生率の上昇
    • 移植片拒絶反応を減らすための個別化医療におけるHLAタイピングの採用
  • 抑制要因
    • 補償の不足と不十分な保険
  • 機会
    • 移植診断とHLAタイピング法の分野における技術的進歩
    • HLAタイピングを補完する免疫抑制療法の優先
  • 課題
    • HLAタイピングの不正確さに関する懸念
• 市場セグメンテーション分析
  • 技術：特異性と再現性が高い分子アッセイ技術の採用
  • 製品とサービス：データの解釈と研究室のワークフロー管理を容易にするソフトウェアとサービスの優先
  • 移植の種類：白血病、リンパ腫、骨髄腫、免疫系疾患に対する幹細胞移植療法の利用が増加
  • 応用：臓器移植の診断アプリケーションにおけるHLAタイピングの使用
  • エンドユーザー：独立したリファレンスラボでの高い普及率により、高スループット機能と拡張性を実現
• 市場動向分析
  • 先進的なヘルスケア開発と確立された市場ベンダーの存在により、南北アメリカにおけるHLAタイピングの拡大が促進されます。
  • アジア太平洋地域では移植用HLAタイピング市場が急速に拡大しており、移植ヘルスケアインフラの改善に向けた先進技術の導入に注力しています。
  • 移植手術の需要の高まりと、質の高いHLAタイピングの商業化に対する政府の支援により、EMEAで有利な市場情勢が創出される
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析

第6章 移植用HLAタイピング市場製品・サービス別

• 機器
• 試薬・消耗品
• ソフトウェアとサービス

第7章 移植用HLAタイピング市場：技術別

• 分子アッセイ技術
• 非分子アッセイ技術

第8章 移植用HLAタイピング市場移植タイプ別

• 臓器移植
• 幹細胞移植
• 組織移植

第9章 移植用HLAタイピング市場：用途別

• 診断アプリケーション
• 調査アプリケーション

第10章 移植用HLAタイピング市場：エンドユーザー別

• 臨床検査室・調査機関
• 病院と移植センター
• 独立リファレンスラボ

第11章 南北アメリカの移植用HLAタイピング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の移植用HLAタイピング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの移植用HLAタイピング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • GenDxがNGS-Turboを発売：Oxford Nanopore Technologiesのシーケンシングデバイスで高解像度 HLAタイピングに革命を起こす
  • Omixonは、オックスフォードナノポアのMinIONプラットフォームと互換性のあるシングルプレックスヒト白血球抗原増幅キット NanoTYPE MONOおよびMONOall RUOを発売しました。
  • JURA Bio、がんにおけるT細胞受容体NK療法の発展に向け、リプレイ製品会社Syenaとの提携を発表
  • オッシウム・ヘルスとビー・ザ・マッチが骨髄移植のアクセス性と治療効率を高めるための提携を発表
  • BriaCellががんプラットフォーム開発のためのNCI助成金を受領
  • テンパス、TScan Therapeuticsとのコンパニオン診断コラボレーションを発表
  • メトロポリス・ヘルスケアが臓器移植用の次世代HLA検査を発表
  • CD Genomics Longseq部門がヒト白血球抗原（HLA）タイピングサービスを発表
  • ガルーダ・セラピューティクス、既製の血液幹細胞技術プラットフォームの発展に向けて6,200万米ドルのシリーズB資金調達を確保
  • FDAは転移性または切除不能なブドウ膜黒色腫に対するT細胞受容体療法の補助診断として使用するためにHLAタイピング検査にDe Novo分類を付与しました。
  • ユーロバイオサイエンティフィックがジェンDxを1億3,230万米ドルで買収
  • Be The Match BioTherapiesとAtara Biotherapeuticsが複数年にわたるパートナーシップ契約を延長

第15章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. HLA TYPING FOR TRANSPLANT MARKET RESEARCH PROCESS
• FIGURE 2. HLA TYPING FOR TRANSPLANT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. HLA TYPING FOR TRANSPLANT MARKET DYNAMICS
• FIGURE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 20. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 22. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 25. HLA TYPING FOR TRANSPLANT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 26. HLA TYPING FOR TRANSPLANT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HLA TYPING FOR TRANSPLANT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INSTRUMENTS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY REAL-TIME PCR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY NON-MOLECULAR ASSAY TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STEM CELL TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TISSUE TRANSPLANTATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY ANTIBODY SCREENING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CHIMERISM MONITORING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY CLINICAL LABORATORIES & RESEARCH INSTITUTION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 66. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 67. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 68. GLOBAL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 79. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 80. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 81. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 82. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 83. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 84. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 85. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 86. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 87. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 88. AMERICAS HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 91. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 92. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 93. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 94. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 95. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 96. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 97. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 98. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 99. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 100. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 101. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 102. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 103. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 104. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 105. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 106. ARGENTINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 107. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 108. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 109. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 110. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 111. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 112. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 113. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 114. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 115. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 116. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 117. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 118. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 119. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 120. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 121. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 122. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 123. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 124. BRAZIL HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 125. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 126. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 127. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 128. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 129. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 130. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 131. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 132. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 133. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 134. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 135. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 136. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 137. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 138. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 139. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 140. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 141. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 142. CANADA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 143. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 144. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 145. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 146. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 147. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 148. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 149. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 150. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 151. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 152. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 153. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 154. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 155. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 156. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 157. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 158. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 159. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 160. MEXICO HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 161. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 162. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 163. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 164. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 165. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 166. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 167. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 168. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 169. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 170. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 171. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 172. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 173. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 174. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 175. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 176. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 177. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 178. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 179. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 180. UNITED STATES HLA TYPING FOR TRANSPLANT MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 181. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 182. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 183. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 184. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 185. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 186. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 187. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 188. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 189. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 190. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 191. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 192. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 193. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 194. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 195. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 196. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 197. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 198. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 199. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 200. ASIA-PACIFIC HLA TYPING FOR TRANSPLANT MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 201. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 202. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 203. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 204. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 205. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 206. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 207. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 208. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 209. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 210. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 211. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 212. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 213. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 214. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 215. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 216. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 217. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 218. AUSTRALIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 219. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 220. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 221. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 222. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 223. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 224. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 225. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 226. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 227. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 228. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 229. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 230. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 231. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 232. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 233. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 234. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 235. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 236. CHINA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 237. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 238. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 239. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 240. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 241. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 242. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 243. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 244. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 245. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 246. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 247. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 248. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 249. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 250. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 251. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 252. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 253. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 254. INDIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 255. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 256. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 257. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 258. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 259. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 260. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 261. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 262. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 263. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 264. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 265. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 266. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 267. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 268. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 269. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 270. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 271. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 272. INDONESIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 273. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 274. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 275. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 276. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 277. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 278. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 279. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 280. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 281. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 282. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 283. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 284. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 285. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 286. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
• TABLE 287. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2018-2023 (USD MILLION)
• TABLE 288. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY DIAGNOSTIC APPLICATIONS, 2024-2030 (USD MILLION)
• TABLE 289. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
• TABLE 290. JAPAN HLA TYPING FOR TRANSPLANT MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
• TABLE 291. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2018-2023 (USD MILLION)
• TABLE 292. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PRODUCT & SERVICE, 2024-2030 (USD MILLION)
• TABLE 293. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 294. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 295. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 296. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY MOLECULAR ASSAY TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 297. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 298. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY PCR-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 299. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2018-2023 (USD MILLION)
• TABLE 300. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY SEQUENCING-BASED MOLECULAR ASSAYS, 2024-2030 (USD MILLION)
• TABLE 301. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2018-2023 (USD MILLION)
• TABLE 302. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY TRANSPLANT TYPE, 2024-2030 (USD MILLION)
• TABLE 303. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
• TABLE 304. MALAYSIA HLA TYPING FOR TRANSPLANT MARKET SIZE, BY APPLICATION, 2024-2030 (USD

[195 Pages Report] The HLA Typing for Transplant Market size was estimated at USD 998.31 million in 2023 and expected to reach USD 1,086.39 million in 2024, at a CAGR 9.09% to reach USD 1,836.58 million by 2030.

Human leukocyte antigen (HLA) typing is a vital process in medicine transplant that involves identifying specific proteins on the surface of cells, known as HLA antigens. The HLA typing for the transplant is used to identify, match, and monitor compatibility between donors and recipients for organ, tissue, or stem cell transplantation. This process is crucial to ensure a successful transplant by reducing the risk of graft rejection and improving overall patient outcomes. Moreover, the rising demand for organ transplants is due to an increase in chronic diseases such as kidney failure, liver cirrhosis, heart failure, diabetes mellitus, and hematological disorders. Precision medicine advancements can lead to personalized approaches based on individual genetic makeup for improved compatibility between donors and recipients. However, there is a need for more trained professionals performing these tests and ethical concerns surrounding organ transplantation consent policies, which restrict the growth of the Human leukocyte antigen (HLA) processes. Furthermore, technological advancements in HLA typing methods such as Next-Generation Sequencing (NGS), PCR-based techniques, and Sanger sequencing contribute to improved accuracy and a faster donor-recipient matching process. Government support through awareness campaigns promoting organ donation and investments in healthcare infrastructure further drive market expansion.

Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility

Molecular assay technologies are increasingly adopted due to their high resolution, specificity, and reproducibility. Sequence-based typing (SBT) techniques involve sequencing exon regions of HLA genes to determine the alleles present in a donor or patient sample. This method provides the highest resolution possible, allowing for precise matching between donors and recipients. In addition, Polymerase chain reaction (PCR) techniques rely on the amplification of target HLA gene regions followed by probe hybridization or restriction fragment length polymorphism (RFLP) analysis to identify specific alleles. Non-molecular assay technologies involve serological and cellular methods for HLA typing. They are primarily used when low-resolution typing is sufficient or where molecular methods may not be accessible due to cost or resource constraints. Serological techniques involve testing serum samples for the presence of specific HLA antigens using antisera obtained from previously typed individuals. Cellular assays assess the compatibility between donor and recipient immune cells by measuring their ability to respond to each other in-vitro.

Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow

Instruments play a crucial role in the HLA typing process as they provide accurate and efficient results for transplant compatibility testing. This includes sequencers, PCR-based instruments, and other laboratory equipment. Reagents and consumables are essential components of the HLA typing process as they ensure reproducibility, sensitivity, specificity, and reliability of test results. This constitutes DNA amplification reagents, DNA sequencing reagents (NGS-based), kits for probe hybridization assays, microarrays/solid-phase assays, and quality control materials & standards used in laboratories. Software and services are integral to the HLA typing process as they facilitate data interpretation, reporting of results, and laboratory workflow management. The software for data analysis, database management systems, and quality assurance programs for proficiency testing are used.

Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases

Organ transplantation involves replacing a damaged or non-functional organ with a healthy one from a donor. HLA typing is essential in this process to minimize the risk of graft rejection due to immune system response, Stem cell transplantation is a therapy for various blood-related disorders such as leukemia, lymphoma, myeloma, and immune system diseases. It involves transplanting healthy hematopoietic stem cells into a patient to replace damaged or dysfunctional cells. HLA typing in stem cell transplantation is vital for ensuring the compatibility of donor and recipient cells, reducing the risk of graft-versus-host disease (GVHD). Tissue transplantation involves grafting healthy donor tissues such as corneas, bone marrow, blood vessels, and skin onto a recipient to restore the function of organs or improve the quality of patient's lives.

Application: Use of HLA typing in diagnostic applications for organ transplantation

HLA typing is preferred for diagnostic applications to ensure compatibility between donors and recipients for organ transplantation, hematopoietic stem cell transplantation, and transfusion medicine. It helps identify suitable matches to reduce the risk of graft rejection and improve patient outcomes. HLA typing is widely used in research applications for population genetics, disease association studies, vaccine development, pharmacogenomics research, and precision medicine initiatives. In addition, it provides efficient tools to generate robust data supporting advancements in medical science.

End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability

Hospitals and transplant centers form the core end-user segment for HLA typing for transplant purposes. These facilities perform tissue typing to determine compatibility between donors and recipients, ensuring successful organ or bone marrow transplants. HLA causes rapid turnaround time, high accuracy, and cost-effective solutions in HLA typing services. Independent reference laboratories provide specialized diagnostic testing services such as HLA typing to hospitals and transplant centers commercially. They are preferred due to high-throughput capabilities, scalability, and technological advancements that enhance efficiency. Research laboratories and academic institutes conduct scientific studies on transplantation biology using advanced techniques such as Next-Generation Sequencing (NGS), PCR-based methods, or Sanger sequencing for HLA typing. This segment primarily seeks innovative technologies, user-friendly platforms, and extensive support services to facilitate the seamless adoption of new methodologies.

Regional Insights

The Human leukocyte antigen (HLA) typing for transplant market is experiencing significant growth worldwide due to technological advancements and the availability of numerous organ transplant procedures. In the United States and Canada, demand for HLA typing is increasing due to growing organ transplantation needs. The National Institutes of Health (NIH) in the U.S. has funded numerous research initiatives to improve HLA typing techniques. Moreover, the Americas human leukocyte antigen (HLA) typing market is expected to grow at a higher rate due to increasing awareness about organ transplantation among both physicians and patients, along with technological advancements leading to more accurate HLA typing results. Europe has witnessed a steady increase in demand for HLA typing services owing to factors such as an aging population that increases the prevalence of chronic diseases requiring organ transplantation. Additionally, favorable reimbursement policies have supported patients undergoing transplant procedures in Europe. Organizations such as the Saudi Society for Organ Transplantation (SSOT) are working to increase awareness and collaborations between nations, such as the Gulf Cooperation Council (GCC) Organ Transplant Program. China, Japan, and India are witnessing an increased demand for HLA typing due to a high prevalence of genetic disorders and growing organ transplantation needs. China's National Natural Science Foundation has funded research on novel HLA typing techniques. Moreover, Japan's Ministry of Health, Labor, and Welfare supports projects such as the Japan Society for Transplantation and Cellular Therapy (JSTCT). In India, government initiatives, such as the 'National Organ and Tissue Transplant Organization (NOTTO) contribute to market growth by increasing public awareness about organ donation.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the HLA Typing for Transplant Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the HLA Typing for Transplant Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the HLA Typing for Transplant Market, highlighting leading vendors and their innovative profiles. These include Agilent Technologies, Inc., BAG Diagnostics GmbH, Becton, Dickinson, and Company, BGI Genomics Co.,Ltd., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, CapitalBio Technology Co., Ltd., CareDx, Inc., CeGaT GmbH, Chugai Pharmaceutical Co., Ltd., Creative Biolabs, Inc., DiaSorin S.p.A., Eurofins Scientific SE, F. Hoffman-La Roche AG, Fujirebio, Inc. by H.U. Group Holdings, Inc., Garuda Therapeutics, GenDx by Eurobio Scientific Group, HEALIOS K.K., Hologic, Inc., Illumina, Inc., Immatics N.V., Immucor, Inc. by Werfen, S.A., ImmunOs Therapeutics AG, Invectys Inc., Laboratory Corporation of America Holdings, Lonza Group Ltd., Merck KGaA, NeoGenomics Laboratories, Inc., OraSure Technologies, Inc., Oxford Nanopore Technologies PLC, Pure MHC, LLC, Pure Protein, LLC, QIAGEN N.V., STEMCELL Technologies Inc., T-Cure Bioscience Inc., Takara Bio Inc., TBG Diagnostics Ltd., TCR2 Therapeutics by Adaptimmune Therapeutics PLC, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the HLA Typing for Transplant Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Product & Service
  • Instruments
  • Reagents & Consumables
  • Software & Services

• Technology
  • Molecular Assay Technologies
    • PCR-Based Molecular Assays
      • Real-Time PCR
      • Sequence-Specific Oligonucleotide-PCR
      • Sequence-Specific Primer-PCR

• Sequencing-Based Molecular Assays
  • Next-Generation Sequencing
  • Sanger Sequencing
• Non-Molecular Assay Technologies

• Transplant Type
  • Organ Transplantation
  • Stem Cell Transplantation
  • Tissue Transplantation

• Application
  • Diagnostic Applications
    • Antibody Screening
    • Chimerism Monitoring

• Research Applications

• End-User
  • Clinical Laboratories & Research Institution
  • Hospitals & Transplant Centers
  • Independent Reference Laboratories

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the HLA Typing for Transplant Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the HLA Typing for Transplant Market?

3. What are the technology trends and regulatory frameworks in the HLA Typing for Transplant Market?

4. What is the market share of the leading vendors in the HLA Typing for Transplant Market?

5. Which modes and strategic moves are suitable for entering the HLA Typing for Transplant Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
    • 5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of reimbursement and inadequate insurance policies
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
    • 5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns regarding the inaccuracy of HLA typing
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
  • 5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
  • 5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
  • 5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
  • 5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
• 5.3. Market Trend Analysis
  • 5.3.1. Advanced Healthcare R&D and presence of established market vendors facilitate the expansion of HLA typing in Americas
  • 5.3.2. Dynamically expanding HLA typing for transplant market in the APAC, with emphasis on advanced technology adoption for offering improved healthcare infrastructure for transplantation
  • 5.3.3. Rising need for transplant procedures and government support for commercializing quality HLA typing to create a favorable market landscape in EMEA
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis

6. HLA Typing for Transplant Market, by Product & Service

• 6.1. Introduction
• 6.2. Instruments
• 6.3. Reagents & Consumables
• 6.4. Software & Services

7. HLA Typing for Transplant Market, by Technology

• 7.1. Introduction
• 7.2. Molecular Assay Technologies
• 7.3. Non-Molecular Assay Technologies

8. HLA Typing for Transplant Market, by Transplant Type

• 8.1. Introduction
• 8.2. Organ Transplantation
• 8.3. Stem Cell Transplantation
• 8.4. Tissue Transplantation

9. HLA Typing for Transplant Market, by Application

• 9.1. Introduction
• 9.2. Diagnostic Applications
• 9.3. Research Applications

10. HLA Typing for Transplant Market, by End-User

• 10.1. Introduction
• 10.2. Clinical Laboratories & Research Institution
• 10.3. Hospitals & Transplant Centers
• 10.4. Independent Reference Laboratories

11. Americas HLA Typing for Transplant Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific HLA Typing for Transplant Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa HLA Typing for Transplant Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
  • 14.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore's MinION Platform
  • 14.3.3. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
  • 14.3.4. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
  • 14.3.5. BriaCell receives NCI grant for cancer platform development
  • 14.3.6. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
  • 14.3.7. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
  • 14.3.8. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
  • 14.3.9. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
  • 14.3.10. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
  • 14.3.11. Eurobio Scientific acquires GenDx for USD 132.3 million
  • 14.3.12. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension

15. Competitive Portfolio

• 15.1. Key Company Profiles
• 15.2. Key Product Portfolio